Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2008 1
2017 1
2018 2
2019 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean harding m (639 results)?
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted AJ, Frølund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H. Lund J, et al. Among authors: hardling m. Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19. Cancer Med. 2018. PMID: 29673108 Free PMC article. Clinical Trial.
Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.
Johansson JE, Bratel J, Hardling M, Heikki L, Mellqvist UH, Hasséus B. Johansson JE, et al. Among authors: hardling m. Bone Marrow Transplant. 2019 Sep;54(9):1482-1488. doi: 10.1038/s41409-019-0468-6. Epub 2019 Feb 4. Bone Marrow Transplant. 2019. PMID: 30718802 Clinical Trial.
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I, Lund J, Gréen H, Gruber A, Alici E, Lauri B, Blimark C, Mellqvist UH, Swedin A, Forsberg K, Carlsson C, Hardling M, Ahlberg L, Lotfi K, Nahi H. Jakobsen Falk I, et al. Among authors: hardling m. Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193. doi: 10.1007/s00280-017-3481-8. Epub 2017 Nov 25. Cancer Chemother Pharmacol. 2018. PMID: 29177954 Free PMC article. Clinical Trial.
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H. Wei Y, et al. Among authors: hardling m. Ann Hematol. 2006 Dec;85(12):841-7. doi: 10.1007/s00277-006-0171-8. Epub 2006 Sep 28. Ann Hematol. 2006. PMID: 17006667 Clinical Trial.
An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H. Nahi H, et al. Among authors: hardling m. Haematologica. 2008 Nov;93(11):1734-8. doi: 10.3324/haematol.13227. Epub 2008 Aug 25. Haematologica. 2008. PMID: 18728022 Free article.